M John Chapman

Summary

Country: France

Publications

  1. ncbi Therapeutic elevation of HDL-cholesterol to prevent atherosclerosis and coronary heart disease
    M John Chapman
    Dyslipoproteinemia and Atherosclerosis Research Unit UMR 551, National Institute for Health and Medical Research INSERM, France
    Pharmacol Ther 111:893-908. 2006
  2. ncbi Spotlight on HDL-raising therapies: insights from the torcetrapib trials
    Anatol Kontush
    INSERM, Unité 551, Pavillon Benjamin Delessert, Hopital de la Pitie, 83 Boulevard de l hopital, 75651 Paris Cedex 13, France
    Nat Clin Pract Cardiovasc Med 5:329-36. 2008
  3. ncbi The potential role of HDL- and LDL-cholesterol modulation in atheromatous plaque development
    M John Chapman
    Institut National de la Sante et de la Recherche Medicale, Hopital de la Pitie, Paris, France
    Curr Med Res Opin 21:S17-22. 2005
  4. ncbi Knockdown expression and hepatic deficiency reveal an atheroprotective role for SR-BI in liver and peripheral tissues
    Thierry Huby
    INSERM U551, Universite Pierre et Marie Curie Paris 6, Dyslipoproteinemia and Atherosclerosis Research Unit, Hopital de la Pitie, Paris, France
    J Clin Invest 116:2767-76. 2006
  5. ncbi Metabolic syndrome and type 2 diabetes: lipid and physiological consequences
    M John Chapman
    Institut National de la Sante et de la Recherche Medicale INSERM, Hopital de la Pitie, Paris, France
    Diab Vasc Dis Res 4:S5-8. 2007
  6. ncbi Beyond the statins: new therapeutic perspectives in cardiovascular disease prevention
    M John Chapman
    Institut National de la Santé et de la Recherche Mé dicale, Hopital de la Pitie, Paris, France
    Cardiovasc Drugs Ther 19:135-9. 2005
  7. ncbi Hypertension and dyslipidaemia in obesity and insulin resistance: pathophysiology, impact on atherosclerotic disease and pharmacotherapy
    M John Chapman
    INSERM National Institute for Health and Medical Research, Unité 551, Hopital de la Pitie, Paris, F 75013, France
    Pharmacol Ther 117:354-73. 2008
  8. ncbi From pathophysiology to targeted therapy for atherothrombosis: a role for the combination of statin and aspirin in secondary prevention
    M John Chapman
    National Institute for Health and Medical Research INSERM, Unité 551, Dyslipoprotéinemies et Athérosclérose Génétique, Métabolisme et Thérapeutique, Hopital de la Pitie, 75651 Paris Cedex 13, France
    Pharmacol Ther 113:184-96. 2007
  9. ncbi Raising high-density lipoprotein cholesterol with reduction of cardiovascular risk: the role of nicotinic acid--a position paper developed by the European Consensus Panel on HDL-C
    M John Chapman
    Institut National de la Sante et de la Recherche Medicale INSERM, Hopital de la Pitie, Paris, France
    Curr Med Res Opin 20:1253-68. 2004
  10. ncbi Functionality of postprandial larger HDL2 particles is enhanced following CETP inhibition therapy
    Natacha Bellanger
    INSERM UMRS939, Hopital de la Pitie, Paris, France
    Atherosclerosis 221:160-8. 2012

Detail Information

Publications90

  1. ncbi Therapeutic elevation of HDL-cholesterol to prevent atherosclerosis and coronary heart disease
    M John Chapman
    Dyslipoproteinemia and Atherosclerosis Research Unit UMR 551, National Institute for Health and Medical Research INSERM, France
    Pharmacol Ther 111:893-908. 2006
    ..Moreover, both agents attenuate aortic atherosclerosis in cholesterol-fed rabbits. Clinical trial data demonstrating the clinical benefits of these drugs on atherosclerosis and CHD are eagerly awaited...
  2. ncbi Spotlight on HDL-raising therapies: insights from the torcetrapib trials
    Anatol Kontush
    INSERM, Unité 551, Pavillon Benjamin Delessert, Hopital de la Pitie, 83 Boulevard de l hopital, 75651 Paris Cedex 13, France
    Nat Clin Pract Cardiovasc Med 5:329-36. 2008
    ..Normalization of both defective HDL function and diminished HDL levels should, therefore, be the focus of pharmacological HDL raising in future studies...
  3. ncbi The potential role of HDL- and LDL-cholesterol modulation in atheromatous plaque development
    M John Chapman
    Institut National de la Sante et de la Recherche Medicale, Hopital de la Pitie, Paris, France
    Curr Med Res Opin 21:S17-22. 2005
    ..Studies show that using nicotinic acid as a monotherapy or in combination with other agents halts plaque progression and translates as a significant reduction in cardiovascular events...
  4. ncbi Knockdown expression and hepatic deficiency reveal an atheroprotective role for SR-BI in liver and peripheral tissues
    Thierry Huby
    INSERM U551, Universite Pierre et Marie Curie Paris 6, Dyslipoproteinemia and Atherosclerosis Research Unit, Hopital de la Pitie, Paris, France
    J Clin Invest 116:2767-76. 2006
    ..These data imply that, in addition to its major atheroprotective role in liver, SR-BI may exert an antiatherogenic role in extrahepatic tissues...
  5. ncbi Metabolic syndrome and type 2 diabetes: lipid and physiological consequences
    M John Chapman
    Institut National de la Sante et de la Recherche Medicale INSERM, Hopital de la Pitie, Paris, France
    Diab Vasc Dis Res 4:S5-8. 2007
    ..An integrated therapeutic approach to correct both the quantitative and qualitative changes characteristic of diabetic dyslipidaemia clearly constitutes a priority for reduction of both macrovascular and microvascular risk...
  6. ncbi Beyond the statins: new therapeutic perspectives in cardiovascular disease prevention
    M John Chapman
    Institut National de la Santé et de la Recherche Mé dicale, Hopital de la Pitie, Paris, France
    Cardiovasc Drugs Ther 19:135-9. 2005
    ..Given that the prevalence of low HDL-C, particularly amongst individuals with CHD, is higher than previously anticipated, combining nicotinic acid and a statin represents an innovative approach to further reducing CHD risk...
  7. ncbi Hypertension and dyslipidaemia in obesity and insulin resistance: pathophysiology, impact on atherosclerotic disease and pharmacotherapy
    M John Chapman
    INSERM National Institute for Health and Medical Research, Unité 551, Hopital de la Pitie, Paris, F 75013, France
    Pharmacol Ther 117:354-73. 2008
    ....
  8. ncbi From pathophysiology to targeted therapy for atherothrombosis: a role for the combination of statin and aspirin in secondary prevention
    M John Chapman
    National Institute for Health and Medical Research INSERM, Unité 551, Dyslipoprotéinemies et Athérosclérose Génétique, Métabolisme et Thérapeutique, Hopital de la Pitie, 75651 Paris Cedex 13, France
    Pharmacol Ther 113:184-96. 2007
    ..This combination may therefore represent an important, cost-efficient therapeutic approach to reduction of cardiovascular risk and prevention of recurrent events in stable CVD...
  9. ncbi Raising high-density lipoprotein cholesterol with reduction of cardiovascular risk: the role of nicotinic acid--a position paper developed by the European Consensus Panel on HDL-C
    M John Chapman
    Institut National de la Sante et de la Recherche Medicale INSERM, Hopital de la Pitie, Paris, France
    Curr Med Res Opin 20:1253-68. 2004
    ..03 mmol/L) in patients with CHD or with a high level of risk for CHD, including patients at high global risk with type 2 diabetes or the metabolic syndrome...
  10. ncbi Functionality of postprandial larger HDL2 particles is enhanced following CETP inhibition therapy
    Natacha Bellanger
    INSERM UMRS939, Hopital de la Pitie, Paris, France
    Atherosclerosis 221:160-8. 2012
    ..To evaluate the impact of CETP inhibition on the capacity of individual postprandial HDL subspecies to promote key steps of the reverse cholesterol transport pathway...
  11. ncbi Atheroprotective reverse cholesterol transport pathway is defective in familial hypercholesterolemia
    Natacha Bellanger
    Institut National de la Sante et de la Recherche Medicale, UMRS 939, Hopital de la Pitie, Paris, France
    Arterioscler Thromb Vasc Biol 31:1675-81. 2011
    ....
  12. ncbi Torcetrapib differentially modulates the biological activities of HDL2 and HDL3 particles in the reverse cholesterol transport pathway
    Giovanna Catalano
    INSERM UMRS551, Hopital de la Pitie, Paris, France
    Arterioscler Thromb Vasc Biol 29:268-75. 2009
    ....
  13. ncbi Human ATP-binding cassette G1 controls macrophage lipoprotein lipase bioavailability and promotes foam cell formation
    Maryline Olivier
    INSERM, UMR_S939, Paris, F 75013, France
    Arterioscler Thromb Vasc Biol 32:2223-31. 2012
    ..The goal of our study was, therefore, to investigate the potential role(s) of ABCG1 in lipid metabolism in humans...
  14. ncbi Atorvastatin reduces postprandial accumulation and cholesteryl ester transfer protein-mediated remodeling of triglyceride-rich lipoprotein subspecies in type IIb hyperlipidemia
    Maryse Guerin
    Institut National de la Santé et de la Recherche Médicale INSERM Unité 551, Dyslipoproteinemia and Atherosclerosis, Hopital de la Pitie, Pavillon Benjamin Delessert, 83 Boulevard de l hopital, 75651 Paris Cedex 13, France
    J Clin Endocrinol Metab 87:4991-5000. 2002
    ....
  15. ncbi Action of ciprofibrate in type IIb hyperlipoproteinemia: modulation of the atherogenic lipoprotein phenotype and stimulation of high-density lipoprotein-mediated cellular cholesterol efflux
    Maryse Guerin
    Institut National de la Santé et de la Recherche Médicale Unité 551, Dyslipoproteinemia and Atherosclerosis, Hopital de la Pitie, 75651 Paris, France
    J Clin Endocrinol Metab 88:3738-46. 2003
    ....
  16. ncbi Postprandial lipemia enhances the capacity of large HDL2 particles to mediate free cholesterol efflux via SR-BI and ABCG1 pathways in type IIB hyperlipidemia
    Zélie Julia
    Institut National de la Santé et de la Recherche Médicale INSERM UMRS939, Hopital de la Pitie, Paris, France
    J Lipid Res 51:3350-8. 2010
    ....
  17. ncbi Blood pressure-lowering response to amlodipine as a determinant of the antioxidative activity of small, dense HDL3
    Boris Hansel
    Service d Endocrinologie Métabolisme, Hopital de la Pitie, Paris, France
    Am J Cardiovasc Drugs 11:317-25. 2011
    ..This study aimed to assess the effect of 1 month's treatment with amlodipine on HDL AOX in hypertensive subjects...
  18. ncbi Impact of LDL apheresis on atheroprotective reverse cholesterol transport pathway in familial hypercholesterolemia
    Alexina Orsoni
    INSERM UMRS939, Hopital de la Pitie, Paris, France
    J Lipid Res 53:767-75. 2012
    ..However, LDL apheresis is without impact on the intrinsic ability of HDL particles to promote either cellular free cholesterol efflux from macrophages or to deliver CE to hepatic cells...
  19. ncbi HDL3-mediated inactivation of LDL-associated phospholipid hydroperoxides is determined by the redox status of apolipoprotein A-I and HDL particle surface lipid rigidity: relevance to inflammation and atherogenesis
    Amal Zerrad-Saadi
    Dyslipidemia and Atherosclerosis Research Unit UMRS 939, National Institute for Health and Medical Research INSERM, Hôpital de Pitié UPMC Paris 6, University Paris Descartes, France
    Arterioscler Thromb Vasc Biol 29:2169-75. 2009
    ....
  20. ncbi Elevated gamma-glutamyltransferase activity and perturbed thiol profile are associated with features of metabolic syndrome
    Philippe Giral
    Unités de Prévention Cardiovasculaire, Groupe Hospitalier Pitié Salpétrière Université Pierre et Marie Curie, 75651 Paris Cedex 13, France
    Arterioscler Thromb Vasc Biol 28:587-93. 2008
    ..We compared the circulating thiol profile in a cohort of patients displaying atherogenic dyslipidemia with and without MS...
  21. ncbi Macrophage apoptosis exerts divergent effects on atherogenesis as a function of lesion stage
    Emmanuel L Gautier
    INSERM U939, Hôpital de Pitié, Paris, France
    Circulation 119:1795-804. 2009
    ..Because apoptotic cell clearance appears to be defective in advanced compared with early atherosclerotic plaques, macrophage apoptosis may differentially affect plaque progression as a function of lesion stage...
  22. ncbi Differential regulation of the human versus the mouse apolipoprotein AV gene by PPARalpha. Implications for the study of pharmaceutical modifiers of hypertriglyceridemia in mice
    Xavier Prieur
    INSERM UMR S, Hopital de la Pitie, Paris, France
    Biochim Biophys Acta 1791:764-71. 2009
    ..They equally emphasize the importance of the choice of a mouse model for investigation of the impact of pharmaceutical modifiers on hypertriglyceridemia...
  23. ncbi Interleukin-6 protects human macrophages from cellular cholesterol accumulation and attenuates the proinflammatory response
    Eric Frisdal
    INSERM, UMR_S939, Dyslipidemia, Inflammation, and Atherosclerosis in Metabolic Diseases, and the ICAN Institute of CardioMetabolism and Nutrition F 75013 and the Université Pierre et Marie Curie Paris 06, UMR_S939, F 75005, Paris, France
    J Biol Chem 286:30926-36. 2011
    ..Such a cellular recycling of free cholesterol may contribute to reduce both foam cell formation and the accumulation of apoptotic bodies as well as intraplaque inflammation in atherosclerotic lesions...
  24. ncbi Inhibition of CETP by torcetrapib attenuates the atherogenicity of postprandial TG-rich lipoproteins in type IIB hyperlipidemia
    Maryse Guerin
    INSERM Unité 551, Hopital de la Pitie, Pavillon Benjamin Delessert, 83, 75651 Paris Cedex 13, France
    Arterioscler Thromb Vasc Biol 28:148-54. 2008
    ..The purpose of this study was to evaluate the impact of torcetrapib on atherogenic TG-rich lipoprotein subfractions in the postprandial phase in Type IIB hyperlipidemia...
  25. ncbi Cholesteryl ester transfer protein expression partially attenuates the adverse effects of SR-BI receptor deficiency on cholesterol metabolism and atherosclerosis
    Majda El Bouhassani
    INSERM UMR S 939, Hopital de la Pitie, F 75013, Paris, France
    J Biol Chem 286:17227-38. 2011
    ..These findings support the contention that the SR-BI pathway contributes in unique ways to cholesterol metabolism and atherosclerosis susceptibility even in the presence of CETP...
  26. ncbi Transcription factor sterol regulatory element binding protein 2 regulates scavenger receptor Cla-1 gene expression
    Morgan Tréguier
    National Institute for Health and Medical Research INSERM, Dyslipoproteinemia and Atherosclerosis Research Unit, Hopital de la Pitie, Paris Cedex 13, France
    Arterioscler Thromb Vasc Biol 24:2358-64. 2004
    ..To define the molecular mechanisms underlying such putative regulation, we evaluated whether Cla-1 is a target gene of the sterol regulatory element binding protein (SREBP) transcription factor family...
  27. ncbi Preferential sphingosine-1-phosphate enrichment and sphingomyelin depletion are key features of small dense HDL3 particles: relevance to antiapoptotic and antioxidative activities
    Anatol Kontush
    Universite Pierre et Marie Curie Paris 6, Paris, France
    Arterioscler Thromb Vasc Biol 27:1843-9. 2007
    ....
  28. ncbi Functional interaction between -629C/A, -971G/A and -1337C/T polymorphisms in the CETP gene is a major determinant of promoter activity and plasma CETP concentration in the REGRESS Study
    Eric Frisdal
    Institut National de la Sante et de la Recherche Medicale, INSERM Unité 551, Dyslipoproteinemia and Atherosclerosis, Paris Cedex, France
    Hum Mol Genet 14:2607-18. 2005
    ....
  29. ncbi Small, dense HDL 3 particles attenuate apoptosis in endothelial cells: pivotal role of apolipoprotein A-I
    Juliana A de Souza
    Dyslipoproteinemia and Atherosclerosis Research Unit UMR939, National Institute for Health and Medical Research INSERM, Hopital de la Pitie, Paris, France
    J Cell Mol Med 14:608-20. 2010
    ..We conclude that small, dense, lipid-poor HDL 3 potently protects endothelial cells from primary apoptosis and intracellular ROS generation induced by mildly oxLDL, and that apoA-I is pivotal to such protection...
  30. ncbi Conventional dendritic cells at the crossroads between immunity and cholesterol homeostasis in atherosclerosis
    Emmanuel L Gautier
    INSERM UMR S U939, Hopital de la Pitie, Paris, France
    Circulation 119:2367-75. 2009
    ..Dendritic cells (DCs) are central to the regulation of immunity, the polarization of the immune response, and the induction of tolerance to antigens. The potential role of DCs in atherosclerosis, however, remains to be defined...
  31. ncbi Cellular SR-BI and ABCA1-mediated cholesterol efflux are gender-specific in healthy subjects
    Giovanna Catalano
    Institut National de la Sante et de la Recherche Medicale, UMR_S551, Dyslipoproteinemia and Atherosclerosis, Paris, France
    J Lipid Res 49:635-43. 2008
    ..72, P < 0.0001), whereas this relationship was not observed in men. In conclusion, HDL-C level may not represent the absolute indicator of the efficiency of the initial step of the reverse cholesterol transport...
  32. ncbi Stimulation of cholesterol efflux by LXR agonists in cholesterol-loaded human macrophages is ABCA1-dependent but ABCG1-independent
    Sandra Larrede
    INSERM UMR S939, Paris, France
    Arterioscler Thromb Vasc Biol 29:1930-6. 2009
    ..We evaluated the relative contribution of the ABCA1 and ABCG1 transporters to cholesterol efflux from human macrophages, and of the capacity of LXR agonists to reduce foam cell formation by stimulating export of cellular cholesterol...
  33. ncbi Enhanced dendritic cell survival attenuates lipopolysaccharide-induced immunosuppression and increases resistance to lethal endotoxic shock
    Emmanuel L Gautier
    Institut National de la Sante et de la Recherche Medicale, Unité Mixte de Recherche S551, Dyslipoproteinemia and Atherosclerosis Research Unit, Hopital de la Pitie, Paris, France
    J Immunol 180:6941-6. 2008
    ..Our study therefore identifies DC death as a key determinant of endotoxin-induced immunosuppression and mortality in mice...
  34. ncbi A normotriglyceridemic, low HDL-cholesterol phenotype is characterised by elevated oxidative stress and HDL particles with attenuated antioxidative activity
    Anatol Kontush
    Dyslipoproteinemia and Atherosclerosis Research Unit U 551, National Institute for Health and Medical Research INSERM, Hopital de la Pitie, 83 Boulevard de l hopital, 75651 Paris Cedex 13, France
    Atherosclerosis 182:277-85. 2005
    ..It is indeterminate as to whether high cardiovascular risk in low HDL-C subjects occurs concomitantly with elevated oxidative stress and/or with biologically dysfunctional HDL particles...
  35. ncbi Enhanced immune system activation and arterial inflammation accelerates atherosclerosis in lupus-prone mice
    Emmanuel L Gautier
    INSERM Unit 551, UPMC Paris 6, Dyslipoproteinemia and Atherosclerosis Research Unit, Hopital de la Pitie, Paris, France
    Arterioscler Thromb Vasc Biol 27:1625-31. 2007
    ..Premature atherosclerosis is a characteristic feature of systemic lupus erythematosus, a prototypic autoimmune disease. The principle cellular and molecular mechanisms which underlie such accelerated atherosclerosis are indeterminate...
  36. ncbi Cholesteryl ester flux from HDL to VLDL-1 is preferentially enhanced in type IIB hyperlipidemia in the postprandial state
    Maryse Guerin
    Institut National de la Sante et de la Recherche Medicale, INSERM Unité 551, Dyslipoproteinemia and Atherosclerosis, Hopital de la Pitie, 75651 Paris, France
    J Lipid Res 43:1652-60. 2002
    ..In conclusion, HDL-CE is preferentially targeted to VLDL-1 via the action of CETP during alimentary lipemia, thereby favoring formation and accumulation of atherogenic CE-rich remnant particles...
  37. ncbi Pharmacological modulation of cholesteryl ester transfer protein, a new therapeutic target in atherogenic dyslipidemia
    Wilfried Le Goff
    , Dyslipoproteinemia and Atherosclerosis: Genetics, Metabolism and Therapy, , , 75651 Cedex 13, Paris, France
    Pharmacol Ther 101:17-38. 2004
    ..The results of clinical trials to evaluate the impact of CETP inhibition on premature atherosclerosis are eagerly awaited...
  38. ncbi Antioxidative activity of HDL particle subspecies is impaired in hyperalphalipoproteinemia: relevance of enzymatic and physicochemical properties
    Anatol Kontush
    Dyslipoproteinemia and Atherosclerosis Research Unit U 551, National Institute for Health and Medical Research, Hopital de la Pitie, Paris, France
    Arterioscler Thromb Vasc Biol 24:526-33. 2004
    ..The impact of such modification on antioxidative activities of HDL subfractions is indeterminate...
  39. ncbi Common promoter C516T polymorphism in the ApoB gene is an independent predictor of carotid atherosclerotic disease in subjects presenting a broad range of plasma cholesterol levels
    Andrei C Sposito
    Dyslipoproteinemia and Atherosclerosis Research Unit, National Institute for Health and Medical Research INSERM, Paris, France
    Arterioscler Thromb Vasc Biol 24:2192-5. 2004
    ..A common polymorphism in the promoter of the apolipoprotein B (apoB) gene, a C to T change at position -516, increases the transcription rate of apoB, resulting in elevated circulating levels of low-density lipoprotein (LDL) cholesterol...
  40. ncbi LDL-apheresis depletes apoE-HDL and pre-β1-HDL in familial hypercholesterolemia: relevance to atheroprotection
    Alexina Orsoni
    INSERM UMR S939, Hopital de la Pitie Salpetriere, Paris, France
    J Lipid Res 52:2304-13. 2011
    ..In LDL-receptor (LDL-R) deficiency, LDL-apheresis may enhance flux through the reverse cholesterol transport pathway and equally attenuate potential biglycan-mediated deposition of apoE-HDL in the arterial matrix...
  41. ncbi Association between a frequent allele of the gene encoding OATP1B1 and enhanced LDL-lowering response to fluvastatin therapy
    Philippe Couvert
    INSERM, UMR S551, Dyslipoproteinemia and Atherosclerosis Research Unit, Hopital de la Pitie, F 75013, Paris, France
    Pharmacogenomics 9:1217-27. 2008
    ..We postulated that genetic variation in SLCO1B1 might affect statin bioavailability, and might therefore influence drug response and potential adverse effects...
  42. ncbi LDL particle subspecies are distinct in their capacity to mediate free cholesterol efflux via the SR-BI/Cla-1 receptor
    Morgan Tréguier
    INSERM U551, Dyslipoproteinemia and Atherosclerosis Research Unit, Hopital de la Pitie, 83 Boulevard de l hopital, 75651 Paris Cedex 13, France
    Biochim Biophys Acta 1771:129-38. 2007
    ..Relative to HDL(2), large buoyant LDL may constitute physiologically-relevant acceptors for cholesterol efflux via Cla-1...
  43. ncbi Pitavastatin: novel effects on lipid parameters
    M John Chapman
    Institut National de la Santé et de la Recherche Médicale UMR S939, Pavillon Benjamin Delessert, Hopital de la Pitie, 83 Blud l Hôpital, 75651 Paris Cedex 13, France
    Atheroscler Suppl 12:277-84. 2011
    ....
  44. ncbi Alterations in lipoprotein defense against oxidative stress in metabolic syndrome
    Boris Hansel
    Service d Endocrinologie Métabolisme, Pavillon Benjamin Delessert, Hopital de la Pitie, 83 Boulevard de l hopital, 75651 Paris Cedex 13, France
    Curr Atheroscler Rep 8:501-9. 2006
    ..Therapeutic normalization of the quantity and the quality of HDL particles may constitute a novel approach to attenuate atherosclerosis and cardiovascular risk in MetS...
  45. ncbi Matrix metalloproteinases, inflammation and atherosclerosis: therapeutic perspectives
    Jean Louis Beaudeux
    Department of Clinical Biochemistry, Groupe Hospitalier Pitie Salpetriere, AP HP, Paris, France
    Clin Chem Lab Med 42:121-31. 2004
    ..This review describes the members of the MMP and TIMP families and discusses the structure, function and regulation of MMP activity; finally, pharmacological approaches to MMP inhibition are highlighted...
  46. ncbi Cholesteryl ester transfer protein: at the heart of the action of lipid-modulating therapy with statins, fibrates, niacin, and cholesteryl ester transfer protein inhibitors
    M John Chapman
    INSERM, UMR S939, Dyslipidemia, Inflammation and Atherosclerosis Research Unit, University Pierre and Marie Curie Paris 6, Pavillon Benjamin Delessert, Hopital de la Pitie, 83 Boulevard de l hopital, Paris Cedex 13, France
    Eur Heart J 31:149-64. 2010
    ..Further studies of these CETP inhibitors, in particular in long-term, large-scale outcome trials, will provide essential information on their safety and efficacy in reducing residual cardiovascular risk...
  47. ncbi Effect of low-fat, fermented milk enriched with plant sterols on serum lipid profile and oxidative stress in moderate hypercholesterolemia
    Boris Hansel
    Service d Endocrinologie Métabolisme, AP HP, Hopital de la Pitie, Paris, France
    Am J Clin Nutr 86:790-6. 2007
    ..Plant sterol (PS)-enriched foods have been shown to reduce plasma LDL-cholesterol concentrations. In most studies, however, PSs were incorporated into food products of high fat content...
  48. ncbi VLDL-induced triglyceride accumulation in human macrophages is mediated by modulation of LPL lipolytic activity in the absence of change in LPL mass
    Dragana Milosavljevic
    National Institute for Health and Medical Research INSERM Unite 551, Hopital de la Pitie, 83, Boulevard de l Hopital, F 75651 Paris Cedex 13, France
    Biochim Biophys Acta 1631:51-60. 2003
    ....
  49. ncbi Optimal pharmacotherapy to combat the atherogenic lipid triad
    M John Chapman
    Dyslipidemia, Inflammation and Atherosclerosis Research Unit, UMR S939, National Institute for Health and Medical Research, Hopital de la Pitie Salpetriere, Paris, France
    Curr Opin Cardiol 26:403-11. 2011
    ..This article focuses on optimizing treatment of atherogenic dyslipidemias involving this lipid triad, emphasizing niacin-based or fibrate-based therapies...
  50. ncbi New dimension of statin action on ApoB atherogenicity
    M John Chapman
    National Institute of Health and Medical Research INSERM, Unit 551, Hopital de la Pitie, Paris, France
    Clin Cardiol 26:I7-10. 2003
    ..By reducing the number of atherogenic lipoprotein particles, rosuvastatin decreases the atherosclerotic burden in hyperlipidemic patients at high risk for CHD and related adverse outcomes...
  51. ncbi Regulation of human CETP gene expression: role of SP1 and SP3 transcription factors at promoter sites -690, -629, and -37
    Wilfried Le Goff
    Institut National de la Santé et de la Recherche Médicale INSERM Unité 551 Dyslipoproteinemias and Atherosclerosis Genetics, Metabolism and Therapy, Hopital de la Pitie, 83 Boulevard de l hopital, 75651 Paris, France
    J Lipid Res 44:1322-31. 2003
    ....
  52. ncbi One third of the variability in HDL-cholesterol level in a large dyslipidaemic population is predicted by age, sex and triglyceridaemia: The Paris La Pitié Study
    Boris Hansel
    Service d Endocrinologie Métabolisme AP HP, Hopital de la Pitie, Paris, France
    Curr Med Res Opin 22:1149-60. 2006
    ....
  53. ncbi Antiatherogenic small, dense HDL--guardian angel of the arterial wall?
    Anatol Kontush
    National Institute for Health and Medical Research INSERM, Unité 551, Hopital de la Pitie, Paris, France
    Nat Clin Pract Cardiovasc Med 3:144-53. 2006
    ..Induction of selective increase in the circulating concentrations of small, dense HDL3 particles with increased antiatherogenic activity seems especially promising, particularly for therapy of atherogenic dyslipidemia...
  54. ncbi LDL particle subclasses in hypercholesterolemia. Molecular determinants of reduced lipid hydroperoxide stability
    Laurent Chancharme
    , Pavillon Benjamin Delessert, , , 75651 Paris Cedex 13, France
    J Lipid Res 43:453-62. 2002
    ..Elevated concentrations of large, CE-rich, light, and intermediate LDL subclasses (LDL1+2, LDL3) in hypercholesterolemia may therefore act as an abundant proatherogenic source of highly unstable LOOH in the arterial wall...
  55. ncbi Biological activities of HDL subpopulations and their relevance to cardiovascular disease
    Laurent Camont
    National Institute for Health and Medical Research INSERM, Dyslipidemia, Inflammation and Atherosclerosis Research Unit UMR 939, Paris F 75013, France
    Trends Mol Med 17:594-603. 2011
    ....
  56. ncbi Statin therapy in acute coronary syndromes: mechanistic insight into clinical benefit
    Andrei C Sposito
    Dyslipoproteinemia and Atherosclerosis Research Unit, National Institute for Health and Medical Research U551, Hopital de la Pitie Salpetriere, Paris, France
    Arterioscler Thromb Vasc Biol 22:1524-34. 2002
    ..In this review, we discuss recent important developments in our knowledge of the clinical evidence of the beneficial effects of early statin therapy in acute coronary syndromes and the biological mechanisms that underlie them...
  57. ncbi Fibrates in 2003: therapeutic action in atherogenic dyslipidaemia and future perspectives
    M John Chapman
    National Institute for Health and Medical Research INSERM, Unit 551, Pavillon Benjamim Delessert, Hopital de la Pitie, 83 bd de l hopital, 75651 Paris Cedex 13, France
    Atherosclerosis 171:1-13. 2003
    ....
  58. ncbi Regulation of the expression of the apolipoprotein(a) gene: evidence for a regulatory role of the 5' distal apolipoprotein(a) transcription control region enhancer in yeast artificial chromosome transgenic mice
    Thierry Huby
    Institut National de la Sante et de la Recherche Medicale, INSERM Unit 551, Dyslipemias and Atherosclerosis Genetics, Metabolism and Therapeutics, Hopital de la Pitie, Paris, France
    Arterioscler Thromb Vasc Biol 23:1633-9. 2003
    ....
  59. ncbi Antiatherogenic function of HDL particle subpopulations: focus on antioxidative activities
    Anatol Kontush
    National Institute for Health and Medical Research INSERM, Dyslipidemia, Inflammation and Atherosclerosis Research Unit UMR 939, Paris, France
    Curr Opin Lipidol 21:312-8. 2010
    ....
  60. ncbi Atorvastatin lowers lipoprotein(a) but not apolipoprotein(a) fragment levels in hypercholesterolemic subjects at high cardiovascular risk
    Sophie Gonbert
    , , , , , 75651 Cedex 13, Paris, France
    Atherosclerosis 164:305-11. 2002
    ..Plasma levels of apo(a) fragments were not modified by either statin. In conclusion, both A10 and S20 significantly lowered Lp(a), although this effect was of greater magnitude in atorvastatin-treated patients...
  61. ncbi Small, dense HDL particles exert potent protection of atherogenic LDL against oxidative stress
    Anatol Kontush
    Dyslipoproteinemia and Atherosclerosis Research Unit U 551, National Institute for Health and Medical Research INSERM, Hopital de la Pitie, Paris, France
    Arterioscler Thromb Vasc Biol 23:1881-8. 2003
    ..The relationship of the structural and functional heterogeneity of HDL particles to protection of LDL against oxidative stress is indeterminate...
  62. ncbi Lipidomics as a tool for the study of lipoprotein metabolism
    Anatol Kontush
    Universite Pierre et Marie Curie Paris 6, Paris, 75013, France
    Curr Atheroscler Rep 12:194-201. 2010
    ....
  63. ncbi Dose-dependent action of atorvastatin in type IIB hyperlipidemia: preferential and progressive reduction of atherogenic apoB-containing lipoprotein subclasses (VLDL-2, IDL, small dense LDL) and stimulation of cellular cholesterol efflux
    Maryse Guerin
    Institut National de la Santé et de la Recherche Médicale INSERM Unité 551, Hopital de la Pitie, Pavillon Benjamin Delessert, 83 Boulevard de l hopital, 75651 Paris, Cedex 13, France
    Atherosclerosis 163:287-96. 2002
    ....
  64. ncbi Functionally defective high-density lipoprotein: a new therapeutic target at the crossroads of dyslipidemia, inflammation, and atherosclerosis
    Anatol Kontush
    Dyslipoproteinemia and Atherosclerosis Research Unit, National Institute for Health and Medical Research, Hopital de la Pitie, 83 Boulevard de l hopital, 75651 Paris Cedex 13, France
    Pharmacol Rev 58:342-74. 2006
    ....
  65. ncbi Niacin and fibrates in atherogenic dyslipidemia: pharmacotherapy to reduce cardiovascular risk
    M John Chapman
    Dyslipidemia, Inflammation and Atherosclerosis Research Unit, UMR S939, National Institute for Health and Medical Research INSERM, Hopital de la Pitie Salpetriere, Paris, France
    Pharmacol Ther 126:314-45. 2010
    ....
  66. ncbi Why is HDL functionally deficient in type 2 diabetes?
    Anatol Kontush
    INSERM Unité 551, Pavillon Benjamin Delessert, Hôpital de Pitié, 83 Boulevard de l hopital, 75651 Paris Cedex 13, France
    Curr Diab Rep 8:51-9. 2008
    ..Therapeutic options for correcting HDL functional deficiency should target hypertriglyceridemia by normalizing circulating levels of triglyceride-rich lipoproteins...
  67. ncbi Serum plasma pregnancy-associated protein A: a potential marker of echogenic carotid atherosclerotic plaques in asymptomatic hyperlipidemic subjects at high cardiovascular risk
    Jean Louis Beaudeux
    Department of Clinical Biochemistry, the National Institute for Health, Paris, France
    Arterioscler Thromb Vasc Biol 23:e7-10. 2003
    ..We evaluated serum PAPP-A levels as a marker of the premature development of atherosclerosis in hyperlipidemic subjects at elevated cardiovascular risk...
  68. ncbi Mildly oxidized LDL particle subspecies are distinct in their capacity to induce apoptosis in endothelial cells: role of lipid hydroperoxides
    Anatol Kontush
    INSERM U.551, Pavillon Benjamin Delessert, , 75651 Paris Cedex 13, France
    FASEB J 17:88-90. 2003
    ..These data are highly relevant to atherogenic hypercholesterolemia, in which the LDL phenotype is dominated by elevated concentrations of light LDL3...
  69. ncbi Cardiovascular diseases. Introduction
    M John Chapman
    Institut National de la Santé et de la Recherche Médicale INSERM UMR S939, Pavillon Benjamin Delessert, Hopital de la Pitie, 83 Blvd l Hôpital, 75651 Paris Cedex 13, France
    Atheroscler Suppl 11:1-2. 2010
    ....
  70. ncbi A novel cholesteryl ester transfer protein promoter polymorphism (-971G/A) associated with plasma high-density lipoprotein cholesterol levels. Interaction with the TaqIB and -629C/A polymorphisms
    Wilfried Le Goff
    Institut National de la Sante et de la Recherche Medicale, Hopital de la Pitie, Unité 321 Lipoprotéines et Athérogénèse, Pavillon Benjamin Delessert, 83 Boulevard de l Hôpital 75651 Paris 13, France
    Atherosclerosis 161:269-79. 2002
    ....
  71. ncbi Optimizing the pharmacology of statins: characteristics of rosuvastatin
    M John Chapman
    Pavillon Benjamin Delassert, INSERM Unite 321, Hopital de la Pitie, 83 Boulevard de l hopital, 75651 Paris Cedex 13, France
    Atheroscler Suppl 2:33-6; discussion 36-7. 2002
    ..Rosuvastatin should constitute an important addition to current lipid-lowering interventions...
  72. ncbi Altered distribution of platelet-activating factor- acetylhydrolase activity between LDL and HDL as a function of the severity of hypercholesterolemia
    Vasilis Tsimihodimos
    Department of Internal Medicine, University of Ioannina, 45110 Ioannina, Greece
    J Lipid Res 43:256-63. 2002
    ..Thus, the ratio of HDL-associated PAF-AH-total plasma enzyme activity may be useful as a potential marker of atherogenicity in subjects with primary hypercholesterolemia...
  73. ncbi Phenotype-dependent and -independent actions of rosuvastatin on atherogenic lipoprotein subfractions in hyperlipidaemia
    Muriel J Caslake
    Department of Pathological Biochemistry, Glasgow Royal Infirmary University NHS Trust, 4th Floor Queen Elizabeth Building, 10 Alexandra Parade, Glasgow G31 2ER, UK
    Atherosclerosis 171:245-53. 2003
    ..Rosuvastatin therefore, in addition to lowering LDL and apoB-concentrations, largely corrected the TG and LDL abnormalities in subjects who had the propensity to develop the atherogenic lipoprotein phenotype...
  74. ncbi Atorvastatin enhances the plasma clearance of chylomicron-like emulsions in subjects with atherogenic dyslipidemia: relevance to the in vivo metabolism of triglyceride-rich lipoproteins
    Andrei C Sposito
    Heart Institute (InCor, , Sao Paulo, Brazil
    Atherosclerosis 166:311-21. 2003
    ..Such effect might implicate in reduction of cardiovascular risk...
  75. ncbi Cholesteryl ester transfer protein: a novel target for raising HDL and inhibiting atherosclerosis
    Philip J Barter
    Hanson Institute and the Department of Cardiology, Royal Adelaide Hospital, Adelaide, Australia
    Arterioscler Thromb Vasc Biol 23:160-7. 2003
    ..Thus, it seems important and timely to test the hypothesis in randomized trials of humans that pharmacological inhibition of CETP retards the development of atherosclerosis...
  76. ncbi Apo B versus cholesterol in estimating cardiovascular risk and in guiding therapy: report of the thirty-person/ten-country panel
    P J Barter
    Heart Research Institute, Camperdown, Sydney, NSW, Australia
    J Intern Med 259:247-58. 2006
    ..The evidence also indicates that the apo B/apo A-I ratio is superior to any of the conventional cholesterol ratios in patients without symptomatic vascular disease or diabetes to evaluate the lipoprotein-related risk of vascular disease...
  77. ncbi Metabolic syndrome features small, apolipoprotein A-I-poor, triglyceride-rich HDL3 particles with defective anti-apoptotic activity
    Juliana A de Souza
    Universite Pierre et Marie Curie Paris 6, Paris F 75013, France
    Atherosclerosis 197:84-94. 2008
    ....
  78. ncbi Metabolic syndrome is associated with elevated oxidative stress and dysfunctional dense high-density lipoprotein particles displaying impaired antioxidative activity
    Boris Hansel
    Dyslipoproteinemia and Atherosclerosis Research Unit, National Institute for Health and Medical Research, , , 75013 Paris, France
    J Clin Endocrinol Metab 89:4963-71. 2004
    ..Induction of selective increase in the circulating concentrations of dense HDL subfractions may represent an innovative therapeutic approach for the attenuation of high cardiovascular risk in MetS...
  79. ncbi Thyroid hormone regulates the hypotriglyceridemic gene APOA5
    Xavier Prieur
    GlaxoSmithKline, 25 Avenue du Quebec, 91951 Les Ulis Cedex, France
    J Biol Chem 280:27533-43. 2005
    ..Additionally, these data suggest that TRbeta may be a potential pharmacological target for the treatment of hypertriglyceridemia...
  80. ncbi Coexistence of foam cells and hypocholesterolemia in mice lacking the ABC transporters A1 and G1
    Ruud Out
    Division of Biopharmaceutics, Leiden Amsterdam Center for Drug Research, Leiden University, The Netherlands
    Circ Res 102:113-20. 2008
    ..In conclusion, even under hypocholesterolemic conditions macrophages can be converted into foam cells, and ABCA1 and ABCG1 play an essential role in the prevention of foam cell formation...
  81. ncbi Apolipoprotein E knockout mice over-expressing human tissue inhibitor of metalloproteinase 1 are protected against aneurysm formation but not against atherosclerotic plaque development
    Clarisse Cuaz-Pérolin
    INSERM U 545, Institut Pasteur de Lille, Departement d Atherosclerose, Lille, France
    J Vasc Res 43:493-501. 2006
    ..We investigated the effect of plasma levels of human tissue inhibitor of metalloproteinase (hTIMP)-1 on arterial lesion development and aneurysm formation in apolipoprotein-E-deficient mice (ApoE(-/-))...
  82. ncbi Vitamin E is not deficient in human atherosclerotic plaques
    Anatol Kontush
    Arterioscler Thromb Vasc Biol 24:e139-40; author reply e141-2. 2004
  83. ncbi Impaired intravascular triglyceride lipolysis constitutes a marker of clinical outcome in patients with stable angina undergoing secondary prevention treatment: a long-term follow-up study
    Andrei C Sposito
    Heart Institute (InCor, Zerbini Foundation, Brasilia, Brazil
    J Am Coll Cardiol 43:2225-32. 2004
    ..21 to 9.14; p = 0.020). CONCLUSIONS: The current study establishes that delayed intravascular TG lipolysis is a strong and independent predictor of evolution to severe angina among patients undergoing secondary prevention therapy of CAD...
  84. ncbi Rosuvastatin reduces MMP-7 secretion by human monocyte-derived macrophages: potential relevance to atherosclerotic plaque stability
    Christophe Furman
    INSERM U-545 and Institut Pasteur de Lille, 1 rue du Professeur Calmette, BP 245, 59019 Lille Cedex, France
    Atherosclerosis 174:93-8. 2004
    ..The effect of rosuvastatin in reducing MMP-7 might protect fibrous caps from degradation and in turn stabilize atheromatous plaques...
  85. ncbi Atorvastatin preferentially reduces LDL-associated platelet-activating factor acetylhydrolase activity in dyslipidemias of type IIA and type IIB
    Vasilis Tsimihodimos
    Department of Internal Medicine, University of Ioannina, Ioannina, Greece
    Arterioscler Thromb Vasc Biol 22:306-11. 2002
    ..The reduction of the LDL-associated PAF-AH activity and the elevation in the ratios of HDL-associated PAF-AH and PON1 activities to LDL plasma levels may represent a new dimension in the antiatherogenic effect of atorvastatin...
  86. ncbi Identification of a novel apolipoprotein(a)-related protein from the European hedgehog (Erinaceus europaeus)
    Andrea R Belczewski
    Rm. A208 Botterell Hall, Department of Biochemistry, Queen's University, Kingston, Ont, Canada K7L 3N6
    DNA Seq 14:15-23. 2003
    ..The function of HaRP-1 remains unclear at present, but may constititute a member of the family of apo(a) proteins that functions in the regulation of lysine-dependent proteolysis...
  87. ncbi Fenofibrate induces HDL-associated PAF-AH but attenuates enzyme activity associated with apoB-containing lipoproteins
    Vasilis Tsimihodimos
    Department of Internal Medicine, University of Ioannina, 45110 Ioannina, Greece
    J Lipid Res 44:927-34. 2003
    ....
  88. ncbi Elevated serum levels of proinflammatory cytokines and biomarkers of matrix remodeling in never-treated patients with familial hypercholesterolemia
    Mariame El Messal
    Faculte des Sciences Ain Chock, Universite Hassan II Ain Chock, Casablanca, Morocco
    Clin Chim Acta 366:185-9. 2006
    ..Although FH is monogenic, wide variation occurs in the onset and severity of atherosclerosis in these patients...
  89. ncbi Serum matrix metalloproteinase-3 and tissue inhibitor of metalloproteinases-1 as potential markers of carotid atherosclerosis in infraclinical hyperlipidemia
    Jean Louis Beaudeux
    Department of Clinical Biochemistry, Groupe Hospitalier Pitie Salpetriere, 47 83 boulevard de l Hopital, Paris Cedex 13 F75651, France
    Atherosclerosis 169:139-46. 2003
    ..Such elevations might reflect enhanced vascular matrix remodeling, a key feature of the progression of atherosclerotic disease...
  90. ncbi Common polymorphism in the MTP promoter attenuates the dyslipidemic and proatherogenic effects of excess body weight
    Andrei C Sposito
    Arterioscler Thromb Vasc Biol 24:e143. 2004